Viral Infection of HSPC Impacts Hematopoiesis

NCT ID: NCT06458504

Last Updated: 2025-03-20

Basic Information

• Recruitment Status: RECRUITING
• Total Enrollment: 45 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2024-10-25
• Study Completion Date: 2026-03-31

Brief Summary

We propose to demonstrate that HIV-1 and SARS-CoV-2 are capable of targeting long-lived HSPC with self-renewal capacities. These progenitors, thus transformed into host cells, can give rise to a durable source of infected cells with an impact on hematopoiesis.

Detailed Description

Virus-induced immunosuppression is the transient or persistent decline of immune cell counts and/or function caused by a virus, favouring its persistence in the host organisms. When sustained, triggered by acute viral replication or maintained by chronic viral infections, virus-induced immunosuppression is a life-threatening condition. It is notoriously observed in chronic HIV-1 infection and even in a considerable fraction of antiretroviral-treated HIV-infected individuals. It is also observed in some individuals recovering from severe and mild-to-moderate COVID-19. Its mechanisms are elusive and efficient therapeutic options are not available. Virus-induced immunosuppression may occur in the periphery (affecting circulating immune cells) or in the bone marrow, affecting hematopoietic stem and progenitor cells (HSPC) and hematopoiesis. Several viruses can infect HSPCs. HIV-1 can directly infect HSC, negatively impacting HSC function and the whole stem cell environment of the bone marrow. Whether HSC can be productively infected by SARS-CoV-2 or just targeted and modulated by it remains uncertain and further studies are required to determine HSPC susceptibility or viral sensing for SARS-CoV-2. Therefore, we will i) Evaluate which hematopoietic stem and progenitor cells (HSPC) are targeted by HIV-1 (in vivo and ex vivo) and SARS-CoV-2 (ex vivo); ii) Evaluate whether these infected HSPC would modulate the bone marrow environment by upregulating inflammatory cytokines detrimental to lymphopoiesis.

Conditions

HIV-1; SARS-CoV-2

Study Design

• Observational Model Type: OTHER
• Study Time Perspective: PROSPECTIVE

Eligibility Criteria

Inclusion Criteria

HIV patients :

• HIV-positive patients with a negative or positive viral load.
• managed at Ambroise Paré Hospital.
• patients with a bone marrow biopsy or myelogram performed as part of their care.

Healthy subjects without HIV - patients with a BM biopsy or myelogram performed as part of their care for a suspected hematological pathology.

Management at Ambroise Paré Hospital.

Exclusion Criteria

-

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Assistance Publique - Hôpitaux de Paris

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Claude CAPRON, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Laboratory of Immunology, Ambroise Paré hospital - APHP

Fernando REAL, PhD

Role: STUDY_DIRECTOR

Center for Infection and Immunity of Lille, INSERM U1019 - CNRS UMR9017, Institut Pasteur de Lille

Locations

Hematology and interne medicine department, Ambroise Paré hospital - APHP

Boulogne-Billancourt, , France

Site Status: RECRUITING

Countries

France

Central Contacts

Claude CAPRON, MD, PhD

Role: CONTACT

claude.capron@aphp.fr

+ 33 01 49 09 58 47

Fernando REAL, PhD

Role: CONTACT

fernando.real@cnrs.fr

+ 33 03 20 87 12 01

Other Identifiers

2024-A00117-40

Identifier Type: REGISTRY

Identifier Source: secondary_id

APHP240419

Identifier Type: -

Identifier Source: org_study_id